Special Issue

Review Special Issue Series: T-cell Based Vaccine Development against Pathogen Infections

Message from the Guest Editor

Current COVID-19 vaccines are designed to induce neutralizing antibodies against SARSCoV-2, which wane over time and are usually evaded by highly infectious variants such as Omicron. SARS-CoV-2-specific T cells induced during infection or vaccination largely maintained their reactivity to viral variants, including Omicron, indicating T cell responses are critical for long-term protective immunity. Thus, the development of T-cell-based vaccines that are able to induce long-term memory T cells might be a reasonable and effective strategy to provide persistent protection against constantly mutating viruses, including SARS-CoV-2. This Special Issue will broadly cover the topics related to T-cell-based vaccines. The interests of this Special Issue include, but are not limited to: (1) dynamics and functionality of T cell response to viruses including SARS-CoV-2 (2) dominant T cell epitopes in various viruses such as SARS-CoV-2 (3) generation and maintenance of long-term memory T cells, and (4) animal models for evaluation of the immunogenicity and efficacy of T-cell-based vaccines designed for humans.

Guest Editor

Prof. Dr. Zheng Zhang

Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, No. 29, Bulan Road, Longgang District, Shenzhen 518112, China

Deadline for manuscript submissions

closed (31 December 2024)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/180060

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI